Dewpoint Therapeutics’ cover photo
Dewpoint Therapeutics

Dewpoint Therapeutics

Biotechnology Research

Boston, MA 13,895 followers

Translating condensate biology into medicine.

About us

Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable.  Please be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Dewpoint Therapeutics. Dewpoint never conducts its interviewing or recruiting processes via messaging apps, freelance sites, or social media platforms (i.e., Facebook, WhatsApp, Telegram, Signal, etc.) except for LinkedIn Recruiter. All communication originating from the Dewpoint team, including those communications relating to any job opportunities, comes through an official Dewpoint email address ending in “@dewpointx.com, the official Dewpoint LinkedIn account, or from the People & Culture team.” We strongly advise you not to provide any personal information if you receive a suspicious inquiry or job offer through any medium other than these official Dewpoint email addresses. Please be further advised that Dewpoint does not accept unsolicited resumes from external recruitment firms. If you suspect any fraudulent activity or misrepresentation in connection with a Dewpoint job opportunity, please report it immediately to contact@dewpointx.com.

Website
https://dewpointx.com
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Boston, MA
Type
Privately Held
Founded
2018
Specialties
biomolecular condensates, oncology, neurodegeneration, cardiopulmonary, virology, insulin resistance, and rare disease

Locations

Employees at Dewpoint Therapeutics

Updates

  • What makes Dewpoint Therapeutics’ approach to drug discovery unique?  💧 We apply revolutionary #condensate science to solve some of the toughest problems in therapeutic development.  👨🔬 We assembled a team of world-class experts to address diseases of high unmet need by targeting central nodes of dysfunction that drive diseases 🔬 We built a state-of-the-art AI/ML-powered integrated platform that supports new target discovery and #cmod discovery and development 💊 We invite you to join us on a tour of our facilities in Seaport Boston, MA: https://lnkd.in/gVrZ-7aB - with Midnight Brunch - Elevated Storytelling

  • At Dewpoint, we’ve long believed that biomolecular condensates are not just a cellular curiosity — they are a fundamental organizing principle of cell biology and a transformative opportunity for drug discovery. That belief is increasingly echoed across the scientific community. Several recent studies independently reinforce what we've observed firsthand: condensates are not a side-story — they are central to how cells work, and how we can intervene when they go wrong. 🔬 “This is a pivotal time in science: independent efforts are converging on the insight that condensates are not just biophysical curiosities, but druggable regulators of cell function. These findings broaden the possibilities in drug discovery by showing that we can target dynamic systems using biophysical principles — opening new paths where traditional approaches have struggled.” — Ann Boija, Ph.D., Head of Research, Dewpoint Therapeutics 📊 “What’s remarkable across these papers is the convergence of data — from imaging and sequencing to molecular modeling. The signal is clear: condensate formation is governed by quantifiable sequence and structural features. That opens the door to systematic prediction and design.” — Francis Carpenter, Head of Data Science and engineering, Dewpoint Therapeutics We’re excited to see the field recognizing the depth and potential of condensate science. To our peers in the scientific and biotech communities: the condensate era is here — and it’s just getting started. Read the full story here:https://lnkd.in/e3TDnXhR #cmod #condensates #drugdiscovery

  • In June we celebrated both the history and future of #Pride, learning about influential and courageous members of the LGBTQIA+ community who advanced gay rights and made significant contributions to society and science and showing our support for LGBTQ youth with notes of appreciation to BAGLY, Inc. and The Trevor Project We also took time to celebrate the unique differences and beauty within our Dewpoint community with a special ongoing art exhibit! #PrideMonth #Inclusivity #HeretoStay 

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
      +1
  • Changes in condensate appearance, including size, shape, intensity and sub-cellular localization encode rich information about mechanisms that drive human disease, and provide a new lens through which we discover the next generation therapeutics, and gain insights into novel mechanisms of action. #cmods #condensatopathy  

    View organization page for Revvity for Life Sciences

    58,857 followers

    Our cell image for June, from Dewpoint Therapeutics, shows induced pluripotent stem cells, derived from a patient with amyotrophic lateral sclerosis (ALS), that have been differentiated into spinal motor neurons. The 20X image acquired on the Opera Phenix high-content imaging system shows the cytoskeleton in white, and nucleoli condensates in magenta. These markers represent one method to monitor the health of neurons. http://ms.spr.ly/6042SQxtn

    • No alternative text description for this image
  • Cardiovascular disease continues to represent a substantial and persistent challenge for millions of patients worldwide. Dewpoint and Bayer | Pharmaceuticals are pushing the boundaries on what is possible in treating cardiovascular disease through the lens of targeting biomolecular condensates. By combining Dewpoint’s unrivaled condensate science expertise, agility and unique drug discovery approach with Bayer’s leadership in cardiovascular R&D and global development infrastructure, together we are transforming the treatment of cardiovascular diseases through innovative therapeutic modalities that rewire disease systems biology through modulation of biomolecular condensates. https://lnkd.in/e_HQ7Kdc #InnovateForPossible #Cmods #Condensates

  • 💡 𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄? The 𝗖𝗗-𝗖𝗢𝗗𝗘 𝗰𝗼𝗻𝗱𝗲𝗻𝘀𝗮𝘁𝗲 𝗲𝗻𝗰𝘆𝗰𝗹𝗼𝗽𝗲𝗱𝗶𝗮 (cd-code.org) is now 𝗰𝗿𝗼𝘀𝘀-𝗿𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲𝗱 𝘄𝗶𝘁𝗵𝗶𝗻 𝗨𝗻𝗶𝗣𝗿𝗼𝘁 (www.uniprot.org), enabling direct access to information about a protein’s known associations with 𝗯𝗶𝗼𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗰𝗼𝗻𝗱𝗲𝗻𝘀𝗮𝘁𝗲𝘀. This integration supports researchers by linking UniProt entries to curated evidence on condensate localization and function, facilitating deeper exploration of 𝗰𝗼𝗻𝗱𝗲𝗻𝘀𝗮𝘁𝗲 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 at the proteome level. Explore the data, connect the dots. #Condensates #CDCODE #UniProt #ProteinFunction #CellBiology #PhaseSeparation #MolecularBiology #Bioinformatics

  • 🧬 𝗡𝗲𝘄 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 𝗱𝗿𝗶𝘃𝗶𝗻𝗴 𝗔𝗟𝗦: Two groundbreaking studies from the groups of Anthony (Tony) Hyman, Simon Alberti and Richard Wheeler reveal novel insights into the molecular mechanisms that lead to ALS pathology, and propose potential new ways to fight this devastating disease. ⚙️ 𝗬𝗮𝗻 𝗲𝘁 𝗮𝗹. (𝗖𝗲𝗹𝗹, 𝟮𝟬𝟮𝟱) show that TDP-43, a key driver of ALS/FTD when dysregulated, undergoes intra-condensate demixing inside stress granules, in an oxidation-dependent manner. This mechanism promotes homotypic TDP-43 interactions to seed toxic aggregates—hallmarks of neurodegeneration. These observations are demonstrated in vitro, in cultured motor neurons, ALS-mouse models and patient samples. https://lnkd.in/g89pTdYg   💊 𝗨𝗲𝗰𝗵𝗶 𝗲𝘁 𝗮𝗹. (𝗡𝗮𝘁 𝗖𝗵𝗲𝗺 𝗕𝗶𝗼𝗹, 𝟮𝟬𝟮𝟱) identify lipoamide as a stress granule small molecule dissolver c-mod, in a condensate phenotypic high throughput screen. The mechanism of action of lipoamide includes partitioning into stress granules and altering the redox sensitivity of SFPQ. Functionally, lipoamide restores nuclear function of TDP-43 and FUS, rescues neurite health in cultured motor neurons, and improves ALS-like phenotypes in vivo in Drosophila and C. elegans model systems. https://lnkd.in/g5VwHhhJ 👉 Together, these findings shed light on the role of oxidation in driving TDP-43 proteinopathy common across >97% of ALS cases, and uncover an unexplored therapeutic avenue through modulating the selective redox environment within the pathological condensates.  #ALS #Neurodegeneration #Condensates #TDP43 #cmods #PhaseSeparation #CellBiology #Therapeutics 

Similar pages

Browse jobs

Funding